Method Development for Forced Degradation of Small Molecule GLP-1 Agonist Orforglipron

Significance of the Topic

GLP-1 receptor agonists play a vital role in managing type II diabetes and obesity by regulating glucose metabolism and appetite. Orforglipron is the first non-peptide small molecule GLP-1 agonist designed for oral administration, offering improved patient compliance and expanded access compared to injectable therapies.

Objectives and Study Overview

This work aimed to develop a stability-indicating LC-MS method for orforglipron and its degradation products. A forced degradation study was used to map degradation pathways, identify impurities, and establish an impurity profiling method compliant with regulatory guidelines.

Methodology

Sample preparation involved acidic, basic, and oxidative stress on orforglipron solutions at elevated temperatures. The systematic screening protocol (SSP) guided method development in three stages:

• pH scouting to compare retention at low (0.1% formic acid) versus high pH (ammonium hydroxide)
• Solvent and column screening using acetonitrile and methanol on various reversed-phase and mixed-mode columns
• Optimization of column length, temperature, and gradient slope to enhance resolution and peak shape

Instrumentation

• Chromatography system: ACQUITY Premier H-Class UPLC
• Detectors: ACQUITY PDA and QDa mass detector (ESI positive mode)
• Columns screened: BEH C18 (2.1×50 and 2.1×100 mm), CSH Phenyl-Hexyl, CSH C18, Atlantis BEH C18 AX, BEH C8 (1.7 µm)
• Mobile phases: water and organic solvents (acetonitrile or methanol) with 0.1% formic acid

Main Results and Discussion

pH scouting showed superior retention and selectivity at acidic conditions, leading to the use of formic acid modifier. Column screening highlighted the 100 mm BEH C18 column with acetonitrile for optimal separation of orforglipron and impurities. Gradient adjustment (starting at 20% organic) and increased column temperature improved resolution of closely eluting degradation products. The final method achieved baseline separation, sharp peak shapes, and met USP 621 criteria (resolution ≥ 2.0, tailing factor 0.8–1.8). QDa mass detection confirmed spectral purity of the orforglipron peak, indicating no co-eluting species.

Benefits and Practical Applications

• Efficient, data-driven method development using SSP
• Robust impurity profiling for quality control and stability testing
• Compliance with USP guidelines ensures regulatory readiness

Future Trends and Applications

Advances in hybrid stationary phases and mass detection technologies will further improve method sensitivity and resolution. The SSP approach can be applied to other small-molecule APIs, and the growth of oral GLP-1 agonists will drive demand for reliable degradation and impurity analyses in pharmaceutical development.

Conclusion

A stability-indicating LC-MS method for orforglipron was successfully developed via forced degradation and systematic screening. The optimized protocol delivers high resolution, spectral purity, and adherence to regulatory standards, supporting the analytical needs for this novel oral GLP-1 agonist.

References

1. Runge S, Wulff BS, Madsen K, Bräuner-Osborne H, Knudsen LB. Different domains of the glucagon and GLP-1 receptors provide the critical determinants of ligand selectivity. Br J Pharmacol. 2003;138(5):787-794.
2. Ronveaux CC, Tomé D, Raybould HE. GLP-1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent signaling. J Nutr. 2015;145(4):672-680.
3. Wharton S et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10).
4. Zelesky T et al. Pharmaceutical forced degradation endpoints: rationale and industry perspective. J Pharm Sci. 2023;112(12).
5. Hong P, McConville PA. A complete solution to perform a systematic screening protocol for LC method development. Waters White Paper. 2018.
6. Iraneta P et al. A review of Waters hybrid particle technology part 3: charged surface hybrid technology. Waters White Paper. 2024.
7. Walter TH et al. A new mixed-mode reversed-phase/anion-exchange stationary phase based on hybrid particles. Waters Application Note. 2020.